Supernus, Inc.
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) develops and commercializes medicines for opioid use disorder (OUD), with its business focused primarily on the United States. Its core products are SUBLOCADE, a monthly extended-release buprenorphine injection, and SUBOXONE Film, a buprenorphine-naloxone medicine taken… From the company’s description.
In fiscal 2025, Supernus, Inc. reported revenue of $1.24B, up 4.3% from fiscal 2024, and net income of $210.00M. Its operating margin was 21.1%, and operations used $27.00M in cash. Over the twelve months to Sep 30, 2026, revenue was $1.37B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Supernus, Inc. does
In the company’s own words
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) develops and commercializes medicines for opioid use disorder (OUD), with its business focused primarily on the United States. Its core products are SUBLOCADE, a monthly extended-release buprenorphine injection, and SUBOXONE Film, a buprenorphine-naloxone medicine taken under the tongue or against the cheek. The company also sells SUBUTEX sublingual tablets in selected markets and distributes SUBOXONE Tablets on a limited transition basis. Its products are used by patients receiving OUD treatment and are prescribed and administered through healthcare providers; sales also depend on coverage and reimbursement by payors. Indivior sells products primarily in the United States, with additional markets including Australia, Canada, France and Germany. In 2025, the United States generated 85% of net revenue. SUBLOCADE generated $856 million in global net sales in 2025, while SUBOXONE Film generated $346 million. Indivior’s history includes its 2014 separation from Reckitt Benckiser’s specialty pharmaceutical business and its 2026 change of domicile from the United Kingdom to the United States.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- ROCKVILLE, MD
- Fiscal year end
- December
- CIK
- 1625297
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Supernus, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Supernus, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Supernus, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Supernus, Inc.’s debt, $90.35M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.63%, maturing 2031 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Supernus, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Supernus, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Supernus, Inc.'s last four quarterly filings that the numbers alone won't show?”